“LORLATINIB IN CRISOTINIB-RESISTANT ALK+ NSCLC PATIENTS. OUR RESULT”. Voprosy Onkologii, vol. 65, no. 3, Mar. 2019, pp. 386-92, https://doi.org/10.37469/0507-3758-2019-65-3-386-392.